Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | MPO | P05164 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | TACR1 | P25103 | 2/20 | 0.64 |
| ▸ | HTR2A | P28223 | 2/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | HTR1D | P28221 | 1/20 | 0.57 |
| ▸ | HTR1B | P28222 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | HTR1E | P28566 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29534005 | 1.00 | MAPT (0.67) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL29534060 | 0.99 | KDM4E (0.65) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL6745399 | 0.99 | MAPT (0.65) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL475351 | 0.92 | MAPT (0.74) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL289044 | 0.92 | MAPT (0.74) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL3873457 | 0.90 | MAPT (0.64) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL21059260 | 0.89 | MAPT (0.70) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL120931 | 0.88 | KDM4E (0.69) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL5065255 | 0.88 | KDM4E (0.65) | MAPTKDM4EMEN1LMNAKMT2A | |
| SCHEMBL17503190 | 0.88 | MAPT (0.72) | MAPTKDM4EMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 477 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114327-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-04-10 | — | — | US | claimed |
| CN-118652320-B | Preparation method and application of instant recombinant human albumin freeze-dried | 通化安睿特生物制药股份有限公司 | 2024-11-05 | — | — | CN | claimed |
| CN-118652320-A | Preparation method and application of instant recombinant human albumin freeze-dried | 通化安睿特生物制药股份有限公司 | 2024-09-17 | — | — | CN | claimed |
| CN-118512402-A | Nanoparticle for delivering medicine in vivo and preparation method thereof | 无锡市南京大学锡山应用生物技术研究所 | 2024-08-20 | — | — | CN | claimed |
| CN-117546833-A | Preparation method of organoid frozen stock solution | 云南昆大生物细胞科技有限公司 | 2024-02-13 | — | — | CN | claimed |
| US-20230398096-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-12-14 | — | — | US | claimed |
| CN-116801719-A | Formulations for cryopreservation of PBMC | SQZ生物技术公司 | 2023-09-22 | — | — | CN | claimed |
| CN-113980118-B | Serum albumin degreasing method | 广东卫伦生物制药有限公司 | 2023-06-06 | — | — | CN | claimed |
| CN-114514035-A | Compositions and methods for delivering therapeutic biologies for treatment of diseases | 伊勒卓菲公司 | 2022-05-17 | — | — | CN | claimed |
| CN-107907603-B | Method for measuring tryptophan related substances in amino acid injection | 华仁药业股份有限公司 | 2021-01-05 | — | — | CN | claimed |
| EP-1112091-A4 | RAPID CRYOBARIC STERILIZATION AND VACCINE PREPARATION | BBI BIOSEQ INC (US) | 2001-08-01 | — | — | EP | claimed |
| EP-1112091-A1 | RAPID CRYOBARIC STERILIZATION AND VACCINE PREPARATION | BBI Bioseq, Inc. (US) | 2001-07-04 | — | — | EP | claimed |
| EP-1095128-A1 | AMINE REACTION COMPOUNDS COMPRISING ONE OR MORE ACTIVE INGREDIENT | THE PROCTER & GAMBLE COMPANY (US) | 2001-05-02 | — | — | EP | claimed |
| WO-2000048641-A1 | RAPID CRYOBARIC STERILIZATION AND VACCINE PREPARATION | BBI BIOSEQ, INC. (US) | 2000-08-24 | — | — | WO | claimed |
| EP-1023899-A1 | AQUEOUS PREPARATION CONTAINING ANTIVIRAL AGENT HAVING PURINE OR PYRIMIDINE SKELETON | Wakamoto Pharmaceutical Co., Ltd. (JP) | 2000-08-02 | — | — | EP | claimed |
| WO-2000002991-A1 | AMINE REACTION COMPOUNDS COMPRISING ONE OR MORE ACTIVE INGREDIENT | THE PROCTER & GAMBLE COMPANY (US) | 2000-01-20 | — | — | WO | claimed |
| WO-2000002981-A2 | LAUNDRY AND CLEANING COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2000-01-20 | — | — | WO | claimed |
| EP-0971024-A1 | Laundry and cleaning compositions | THE PROCTER & GAMBLE COMPANY (US) | 2000-01-12 | — | — | EP | claimed |
| EP-0971025-A1 | Amine reaction compounds comprising one or more active ingredient | THE PROCTER & GAMBLE COMPANY (US) | 2000-01-12 | — | — | EP | claimed |
| US-6013773-A | STABLE SOLUTION CONTAINING SOMATOTROPIN, NICOTINAMIDE AND SODIUM ACETYLTRYPTOPHANE ; FOR INCREASED SOLUBILITY OF SOMATOTROPIN | MITSUI CHEMICALS, INC. (JP) | 2000-01-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114327-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | MAPT 240/4885KDM4E 1970/4885MEN1 2674/4885 |
| US-20230398096-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | MAPT 240/4885KDM4E 1970/4885MEN1 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.